Lv2
200 积分 2025-04-14 加入
TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection
2天前
求助中
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
2个月前
已完结
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
3个月前
已关闭
Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard-of-Care Therapy in Individuals with Primary IgAN: Week 96 Data from an Open-Label Phase 1b Study
3个月前
已关闭
Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
3个月前
已完结
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
5个月前
已完结
Tremelimumab: First Approval
5个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
6个月前
已完结
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis
6个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
8个月前
已完结
皖公网安备34019202002308
